SYGNIS AG revised earnings guidance for the financial year 2018. For the year, the company revised its guidance for the financial year 2018 following the recently announced acquisition of TGR Biosciences. After assessing the impact of the TGR Biosciences acquisition on the expected results for 2018, SYGNIS has raised its 2018 full year revenue guidance to EUR 13 million to EUR 14 million compared to previous revenue guidance of EUR 11 to EUR 12 million, an increase of at least 67% against 2017 reported revenues, and continues to expect an overall positive EBITDA for the year.